Learn
Patient Navigation Program
Find Treatment Options
Expanded Access Programs
Brain Tumor Symptoms
Guide For High Grade Tumors
Guide For Low Grade Tumors
Checklist For Newly Diagnosed
Video Library
Noteworthy Treatments
Brain Tumor News
Survivor Stories
Fundraising
DC-Vax
Modeyso™(Onc-201) for DIPG/DMG
Optune
Temodar (Temozolomide)
GammaTile
Newsletter
Subscribe
Change Email
Unsubscribe
Archives
Virtual Trial
What is it?
Join
Submit An Update
Map of Participants
Resources
Copayment Assistance Program
Drug Discount Card
Brain Tumor Centers
Support Groups
Links To Other Resources
Books
Memorials
About Us
Musella Foundation
Research Grants
Recent Additions To Website
Privacy Policy
Ethics And Values
Our Sponsors
Financials
Contact
donations
Sponsored by
Please click on the above banner for more details
Brain Tumor News
Brain Tumor Conferences / Events
Brain Tumor News!
Subscribe to our Free Brain Tumor News Blast E-Mail Newsletter
Brain Tumor News Blast Archives
Submit a press release or abstract
Recent additions to this website!
Brain Tumor News!
Note: The comments under each article title are the
opinion
of our president, Al Musella, DPM,
and do not reflect official policy of the Musella Foundation!
Displaying Stories 5181 to 5200 of 7,668
Previous 20
Next 20
06/08/04
The risk for malignant primary adult-onset glioma in a large, multiethnic, managed-care cohort: cigarette smoking and other lifestyle behaviors.
06/08/04
Histopathological findings in autopsied glioblastoma patients treated by mixed neutron beam BNCT.
06/08/04
A phase I/II trial of BMS-247550 for patients with recurrent high-grade gliomas.
06/08/04
A phase I/II trial of PTK787/ZK 222584 (PTK/ZK), a novel, oral angiogenesis inhibitor, in combination with either temozolomide or lomustine for patients with recurrent glioblastoma multiforme (GBM).
06/08/04
A phase I/II trial of single-agent PTK 787/ZK 222584 (PTK/ZK), a novel, oral angiogenesis inhibitor, in patients with recurrent glioblastoma multiforme (GBM).
06/08/04
A phase II trial of conventional radiation therapy (XRT) plus high dose tamoxifen (TAM) for the treatment of supratentorial glioblastoma multiforme (GBM): RTOG protocol BR-0021.
06/08/04
A phase II trial of erlotinib (OSI-774) in patients (pts) with recurrent malignant gliomas (MG) not on EIAEDs.
06/08/04
A phase II trial of LY317615 in patients with recurrent high grade gliomas.
06/08/04
Adjuvant chemotherapy with temozolomide and pegylated liposomal doxorubicin in the first-line therapy of patients with glioblastoma ¨C a phase-II trial.
06/08/04
An intergroup randomized controlled clinical trial (RCT) of chemotherapy plus radiation (RT) versus RT alone for pure and mixed anaplastic oligodendrogliomas: Initial report of RTOG 94-02.
06/08/04
Baseline pathological and radiological assessment of tumor angiogenesis predicts survival in patients with oligodendrogliomas.
06/08/04
Carboplatin and etoposide (CE) chemotherapy in patients with recurrent or progressive oligodendroglial tumors.
06/08/04
Combination chemotherapy with gemcitabine and docetaxel for recurrent germ cell tumors in the central nervous system.
06/08/04
Combined administration of imatinib mesylate and ionizing radiation leads to increased radiosensitivity in the human glioblastoma cell line RuSi RS1.
06/08/04
Concordance of FDG-PET scan and MRI- spectroscopy in primary and metastatic intracranial tumors.
06/08/04
Efficacy of platinum-based chemotherapy after cranial irradiation in patients with brain metastasis from non-small cell lung cancer.
06/08/04
High failure rate in spinal ependymomas with long-term follow-up.
06/08/04
High-dose (HD) irinotecan in patients with recurrent unresectable high-grade gliomas on glucoronidation-enhancing anticonvulsants (GEACs): A phase I/II study.
06/08/04
How costly is brain cancer? Healthcare services use and costs from across the US.
06/08/04
Imatinib (STI 571) is active in patients (PTS) with high-grade gliomas progressing on standard therapy.
Displaying Stories 5181 to 5200 of 7668
Previous 20
Next 20
Our privacy / cookie policy has changed.
Click HERE to read it!